ArticleTherapeutics and clinical risk management2017

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Mary Lou Affronti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.